Alembic Pharmaceuticals
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Alembic Pharmaceuticals is positioned for a growth inflection, particularly in its U.S. generics and API segments, which reported impressive growth rates of 49% and 33% respectively in Q1 FY27. Management's strategic pivot towards complex specialty products, including peptides and injectables, is expected to enhance long-term margins despite initial pressures from R&D investments. The company's optimistic outlook is supported by strong performance in the U.S. market, driven by exclusive product launches and a focus on operational excellence. Vista's forecast anticipates accelerating revenue growth beyond historical levels, with stable margins and a fair valuation aligned with intrinsic value. However, the competitive landscape in the U.S. generics market and potential regulatory hurdles remain critical watchpoints. Over the next 12-24 months, Alembic's growth will be influenced by its ability to scale new product launches and navigate pricing pressures. Key opportunities include expanding its specialty portfolio and geographic diversification, while headwinds may arise from rising input costs and increased competition in the biosimilars space
Why We Like This Stock
- Strong growth in U.S. generics and API segments, with management raising revenue guidance
- Strategic focus on high-value specialty products is expected to enhance long-term margins
- Geographic diversification and new product launches are driving operational expansion
Things To Watch Out For
- Intense competition in the U.S. generics market may pressure margins
- Regulatory hurdles could delay product launches and impact revenue
- Rising input costs and pricing pressures in key markets pose risks to profitability
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 6,229 | 6,672 | 7,345 | 8,287 | 9,408 |
| Profit Before Tax (Cr.) | 629 | 690 | 761 | 850 | 992 |
| PBT Margin | 10.1% | 10.3% | 10.4% | 10.3% | 10.5% |
| Net Profit (Cr.) | 565 | 584 | 622 | 697 | 808 |
| Earnings Per Share | 28.7 | 29.8 | 31.8 | 35.2 | 41.1 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| ICICI Securities | ► Add | 910 | 10-Sep-2026 |
| Deven Choksey | ► Hold | 836 | 05-Aug-2026 |
| HSBC | ► Add | 800 | 08-May-2026 |
Company Overview
Show Company Profile
Alembic Pharmaceuticals Limited, an integrated pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products in India and internationally. The company provides products in various therapeutic areas, such as cardiology, orthopaedics, anti-diabetic, ophthalmology, gynaecology, nephrology, gastrology, urology, dermatology, anti-infective, cold and cough, and animal health; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. Alembic Pharmaceuticals Limited was founded in 1907 and is headquartered in Vadodara, India.